AlphaSimPlex Group’s NovoCure NVCR Stock Holding History

AlphaSimPlex Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,026	Closed	-$235K	–	181
2021 Q3	$235K	Buy	+2,026	New	+$306K	0.19%	192

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaSimPlex Group's NVCR Position: Q4 2021 in Review

AlphaSimPlex Group sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 2,026 shares — an estimated $235K sold.

AlphaSimPlex Group first reported a position in NVCR in Q3 2021 and held it in 1 quarter. The position peaked at $235K in Q3 2021. 311 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

AlphaSimPlex Group reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
AlphaSimPlex Group sold 2,026 NovoCure shares in Q4 2021, an estimated $235K.
AlphaSimPlex Group first reported a position in NovoCure in Q3 2021 and held it in 1 quarter.
AlphaSimPlex Group's NovoCure position peaked at $235K in Q3 2021.
311 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on AlphaSimPlex Group's 13F filing for Q4 2021, filed 10 Feb 2022.